307 related articles for article (PubMed ID: 25486419)
21. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
[TBL] [Abstract][Full Text] [Related]
22. Eczema vaccinatum.
Reed JL; Scott DE; Bray M
Clin Infect Dis; 2012 Mar; 54(6):832-40. PubMed ID: 22291103
[TBL] [Abstract][Full Text] [Related]
23. Filaggrin deficiency promotes the dissemination of cutaneously inoculated vaccinia virus.
Oyoshi MK; Beaupré J; Venturelli N; Lewis CN; Iwakura Y; Geha RS
J Allergy Clin Immunol; 2015 Jun; 135(6):1511-8.e6. PubMed ID: 25649082
[TBL] [Abstract][Full Text] [Related]
24. Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax.
Davies DH; Wyatt LS; Newman FK; Earl PL; Chun S; Hernandez JE; Molina DM; Hirst S; Moss B; Frey SE; Felgner PL
J Virol; 2008 Jan; 82(2):652-63. PubMed ID: 17977963
[TBL] [Abstract][Full Text] [Related]
25. Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination.
Grosenbach DW; Jordan R; King DS; Berhanu A; Warren TK; Kirkwood-Watts DL; Tyavanagimatt S; Tan Y; Wilson RL; Jones KF; Hruby DE
Vaccine; 2008 Feb; 26(7):933-46. PubMed ID: 18226434
[TBL] [Abstract][Full Text] [Related]
26. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.
Stittelaar KJ; van Amerongen G; Kondova I; Kuiken T; van Lavieren RF; Pistoor FH; Niesters HG; van Doornum G; van der Zeijst BA; Mateo L; Chaplin PJ; Osterhaus AD
J Virol; 2005 Jun; 79(12):7845-51. PubMed ID: 15919938
[TBL] [Abstract][Full Text] [Related]
27. Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA).
Abdalrhman I; Gurt I; Katz E
Vaccine; 2006 May; 24(19):4152-60. PubMed ID: 16603280
[TBL] [Abstract][Full Text] [Related]
28. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge.
Empig C; Kenner JR; Perret-Gentil M; Youree BE; Bell E; Chen A; Gurwith M; Higgins K; Lock M; Rice AD; Schriewer J; Sinangil F; White E; Buller RM; Dermody TS; Isaacs SN; Moyer RW
Vaccine; 2006 Apr; 24(17):3686-94. PubMed ID: 16430997
[TBL] [Abstract][Full Text] [Related]
29. Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge.
He Y; Meseda CA; Vassell RA; Merchlinsky M; Weir JP; Weiss CD
Vaccine; 2010 Jan; 28(3):699-706. PubMed ID: 19887133
[TBL] [Abstract][Full Text] [Related]
30. The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments
de Freitas LFD; Oliveira RP; Miranda MCG; Rocha RP; Barbosa-Stancioli EF; Faria AMC; da Fonseca FG
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567985
[TBL] [Abstract][Full Text] [Related]
31. Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara.
Staib C; Suezer Y; Kisling S; Kalinke U; Sutter G
J Gen Virol; 2006 Oct; 87(Pt 10):2917-2921. PubMed ID: 16963750
[TBL] [Abstract][Full Text] [Related]
32. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.
Seaman MS; Wilck MB; Baden LR; Walsh SR; Grandpre LE; Devoy C; Giri A; Noble LC; Kleinjan JA; Stevenson KE; Kim HT; Dolin R
J Infect Dis; 2010 May; 201(9):1353-60. PubMed ID: 20350190
[TBL] [Abstract][Full Text] [Related]
33. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
Parrino J; McCurdy LH; Larkin BD; Gordon IJ; Rucker SE; Enama ME; Koup RA; Roederer M; Bailer RT; Moodie Z; Gu L; Yan L; Graham BS;
Vaccine; 2007 Feb; 25(8):1513-25. PubMed ID: 17126963
[TBL] [Abstract][Full Text] [Related]
34. Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response.
Oyoshi MK; Elkhal A; Kumar L; Scott JE; Koduru S; He R; Leung DY; Howell MD; Oettgen HC; Murphy GF; Geha RS
Proc Natl Acad Sci U S A; 2009 Sep; 106(35):14954-9. PubMed ID: 19706451
[TBL] [Abstract][Full Text] [Related]
35. Itch-associated scratching contributes to the development of dermatitis and hyperimmunoglobulinaemia E in NC/Nga mice.
Hashimoto Y; Takaoka A; Sugimoto M; Honma Y; Sakurai T; Futaki N; Arai I
Exp Dermatol; 2011 Oct; 20(10):820-5. PubMed ID: 21771100
[TBL] [Abstract][Full Text] [Related]
36. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.
Drexler I; Staib C; Kastenmuller W; Stevanović S; Schmidt B; Lemonnier FA; Rammensee HG; Busch DH; Bernhard H; Erfle V; Sutter G
Proc Natl Acad Sci U S A; 2003 Jan; 100(1):217-22. PubMed ID: 12518065
[TBL] [Abstract][Full Text] [Related]
37. Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model.
El-Gogo S; Staib C; Meyr M; Erfle V; Sutter G; Adler H
Vaccine; 2007 May; 25(20):3934-45. PubMed ID: 17433507
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART.
Cosma A; Nagaraj R; Staib C; Diemer C; Wopfner F; Schätzl H; Busch DH; Sutter G; Goebel FD; Erfle V
AIDS Res Hum Retroviruses; 2007 Jun; 23(6):782-93. PubMed ID: 17604541
[TBL] [Abstract][Full Text] [Related]
39. Induction of atopic eczema/dermatitis syndrome-like skin lesions by repeated topical application of a crude extract of Dermatophagoides pteronyssinus in NC/Nga mice.
Kang JS; Lee K; Han SB; Ahn JM; Lee H; Han MH; Yoon YD; Yoon WK; Park SK; Kim HM
Int Immunopharmacol; 2006 Oct; 6(10):1616-22. PubMed ID: 16919834
[TBL] [Abstract][Full Text] [Related]
40. Susceptibility to vaccinia virus infection and spread in mice is determined by age at infection, allergen sensitization and mast cell status.
Domenico J; Lucas JJ; Fujita M; Gelfand EW
Int Arch Allergy Immunol; 2012; 158(2):196-205. PubMed ID: 22286752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
